| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8787933 | Journal of Thoracic Oncology | 2017 | 15 Pages |
Abstract
This is, to the best of our knowledge, the first reported case of combination EGFR tyrosine kinase inhibitor therapy tailored to the allelic conformation of T790M and C797S mutation that resulted in brief clinical improvement without toxicity.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Surein M.B.B.S., Hongdo PhD, Ashan MLabMed, Paul MD, Alexander PhD, Thomas M.B.B.S., PhD,